Clinical Trial Update: Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types [Phase 1]

View source ↗

Summary

Phase 1 trial of BI 836845 to determine the maximum tolerated dose when given intravenously every 3 weeks, with a subsequent weekly dosing schedule in selected …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• BI 836845

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2025-07-11